What is the long-form title of Guidance 152?

What is the long-form title of Guidance 152?

• A. Evaluating the Safety of Bovine Drugs with Regard to Bacteria of Human Health Concern
• B. Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern
• C. Guidance for Antimicrobial Use in Animals
• D. Bacteria and Health in Animals Guidance

Answer: (B)

The main idea being tested is recognizing the exact scope of Guidance 152, which is about evaluating the safety of antimicrobial drugs used in animals in terms of their microbiological impact on bacteria that matter for human health. This long-form title is the best answer because it names both parts of the scope: the subject (antimicrobial drugs used in animals, specifically new animal drugs) and the outcome of concern (their microbiological effects on bacteria that could affect human health). It signals that the guidance is not just about animal safety or toxicology, but about regulatory evaluation of how a drug might influence microbial populations and resistance patterns that could impact people. In practice, this means assessing whether approving a new antimicrobial for animals could promote resistance, alter the animal microbiome in ways that affect human pathogens, or otherwise pose risks to human health through microbial pathways. Context helps: antimicrobial resistance is a key public health consideration when approving drugs for animals. Trials and data are needed to show that a new drug won’t unduly select for resistant bacteria or transfer resistance to human health–relevant bacteria, preserving efficacy for treating human infections. Other titles miss important elements: they might be too broad or focus on general antimicrobial use, omit the emphasis on new animal drugs, or fail to specify the microbiological effects on bacteria of human health concern.

The main idea being tested is recognizing the exact scope of Guidance 152, which is about evaluating the safety of antimicrobial drugs used in animals in terms of their microbiological impact on bacteria that matter for human health.

This long-form title is the best answer because it names both parts of the scope: the subject (antimicrobial drugs used in animals, specifically new animal drugs) and the outcome of concern (their microbiological effects on bacteria that could affect human health). It signals that the guidance is not just about animal safety or toxicology, but about regulatory evaluation of how a drug might influence microbial populations and resistance patterns that could impact people. In practice, this means assessing whether approving a new antimicrobial for animals could promote resistance, alter the animal microbiome in ways that affect human pathogens, or otherwise pose risks to human health through microbial pathways.

Context helps: antimicrobial resistance is a key public health consideration when approving drugs for animals. Trials and data are needed to show that a new drug won’t unduly select for resistant bacteria or transfer resistance to human health–relevant bacteria, preserving efficacy for treating human infections.

Other titles miss important elements: they might be too broad or focus on general antimicrobial use, omit the emphasis on new animal drugs, or fail to specify the microbiological effects on bacteria of human health concern.